|
Prostate cancer is the second-leading
cancer killer of American men. An estimated 189,000 US men will be diagnosed
with prostate cancer this year and 30,200 will die from the disease, according
to the American Cancer Society.
Though annual blood tests for
prostate cancer are often recommended by doctors, many men hoping to detect
early signs of the malignancy may not need the test so frequently.
Men with a very low reading
on their initial prostate specific antigen (PSA) blood test can be tested
once every 5 years with little chance that their PSA levels will "skyrocket"
in the meantime.
PSA is a protein that, when
elevated, can indicate prostate cancer. A very low PSA level is below
1 nanogram per milliliter of blood. A PSA level of 4 ng/mL or higher is
considered elevated, while 3 ng/mL is viewed as normal. In the study,
more than 90% of study participants had normal PSA levels at baseline.
The study of nearly 28,000
US men also concluded that a PSA test every 2 years would suffice for
men with a baseline PSA of 1 to 1.9 ng/mL.
The American Cancer Society
and the American Urological Association support annual PSA testing and
digital rectal exams beginning at age 50 for most men.
However, many medical groups,
including the National Cancer Institute, leave the decision up to patients
and their doctors because no study to date had confirmed that screening
actually saves lives. ASCO has no position on prostate cancer screening,
according to a spokesperson.
If
US men followed the guidelines of the study, there would be a 55% decrease
in the number of annual screenings at a cost savings of $500 million to
$1 billion.
And 99% of men would have a
normal PSA result on the years that they skipped testing.
As for men with baseline PSA
levels of 2 to 3.9, they should probably be more closely watched, with
annual screenings, because they are more likely to experience elevations
in their PSA levels that put them in more of a potential danger zone.
The findings were drawn from
a sample of 27,863 men aged 55 to 74 participating in a large ongoing
study by the National Cancer Institute. One of the goals of this study
is to determine whether prostate cancer screening, both PSA testing and
digital rectal exams, are beneficial.
Annual
Meeting of the American Society of Clinical Oncology Orlando, FA May 20,
2002
|